US OptionsDetailed Quotes
VNDA241220C5000
- 0.14
- -0.07-33.33%
15min DelayClose Dec 4 16:00 ET
0.20High0.14Low
0.20Open0.21Pre Close74 Volume1.85K Open Interest5.00Strike Price1.13KTurnover46.69%IV6.20%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type0.3952Delta0.8168Gamma38.72Leverage Ratio-0.0060Theta0.0008Rho15.30Eff Leverage0.0039Vega
Vanda Pharmaceuticals Stock Discussion
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals confirmed receipt of a second unsolicited, non-binding proposal from Cycle Group Holdings to acquire the company for $8.00 per share in cash. This proposal, received on September 23, 2024, is economically identical to the previously rejected offer from May 24, 2024.
Vanda's Board of Directors unanimously dete...
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
Cycle Pharmaceuticals has reaffirmed its proposal to acquire Vanda Pharmaceuticals (NASDAQ: VNDA) for $8.00 per share in an all-cash transaction. This offer represents an 80% premium to Vanda's closing share price on October 11, 2024, and values the company at $488 million on a fully diluted basis.
Cycle criticizes Vanda's board for refusing to engage and fo...
No comment yet